M2-polarized macrophages contribute to the decreased sensitivity of EGFR-TKIs treatment in patients with advanced lung adenocarcinoma. (Q54337332)

28 May 2018

title

M2-polarized macrophages contribute to the decreased sensitivity of EGFR-TKIs treatment in patients with advanced lung adenocarcinoma. (English)

1 reference

28 May 2018

1 reference

Bicheng Zhang

1

1 reference

28 May 2018

Yafei Zhang

2

1 reference

28 May 2018

Jie Zhao

3

1 reference

28 May 2018

Zhigang Wang

4

1 reference

28 May 2018

Tingting Wu

5

1 reference

28 May 2018

Wuling Ou

6

1 reference

28 May 2018

Jun Wang

7

1 reference

28 May 2018

Bo Yang

8

1 reference

28 May 2018

Yong Zhao

9

1 reference

28 May 2018

Zhiguo Rao

10

1 reference

28 May 2018

Jianfei Gao

11

1 reference

28 May 2018

publication date

18 July 2014

1 reference

28 May 2018

published in

Medical Oncology

1 reference

28 May 2018

volume

31

1 reference

28 May 2018

issue

8

1 reference

28 May 2018

page(s)

127

1 reference

28 May 2018

https://scigraph.springernature.com/pub.10.1007/s12032-014-0127-0

exact match

0 references

cites work

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0127-0

Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0127-0

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0127-0

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0127-0

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0127-0

Epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0127-0

Mutations and response to epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0127-0

Macrophage diversity enhances tumor progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0127-0

Macrophage activation and polarization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0127-0

Stromal macrophage expressing CD204 is associated with tumor aggressiveness in lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0127-0

Tumor-associated macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0127-0

Prognostic significance of macrophage infiltration in leiomyosarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0127-0

Tumor-associated macrophage correlated with angiogenesis and progression of mucoepidermoid carcinoma of salivary glands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0127-0

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0127-0

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0127-0

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0127-0

The many faces of macrophage activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0127-0

Biochemical and functional characterization of three activated macrophage populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0127-0

Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0127-0

M2-polarized tumor-associated macrophages are associated with poor prognoses resulting from accelerated lymphangiogenesis in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0127-0

Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0127-0

Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0127-0

Alternatively activated RAW264.7 macrophages enhance tumor lymphangiogenesis in mouse lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0127-0

M2-polarized macrophages promote metastatic behavior of Lewis lung carcinoma cells by inducing vascular endothelial growth factor-C expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0127-0

Stromal fibroblasts in cancer initiation and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0127-0

First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0127-0

Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0127-0

Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0127-0

Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0127-0

Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0127-0

Ratio of M2 macrophage expression is closely associated with poor prognosis for Angioimmunoblastic T-cell lymphoma (AITL)

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25034365

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25034365

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S12032-014-0127-0

1 reference

28 May 2018

PubMed ID

25034365

1 reference

28 May 2018